Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Vocuff is a multi-ingredient pharmaceutical product developed and marketed by Skyways Healthcare, an Indian generic pharmaceutical company. It is typically formulated as an oral syrup containing a combination of levosalbutamol (a beta-2 adrenergic agonist), ambroxol hydrochloride (a mucolytic agent), and guaifenesin (an expectorant). This combination is indicated for the symptomatic treatment of productive cough associated with respiratory conditions such as bronchial asthma, bronchitis, and chronic obstructive pulmonary disease (COPD). Levosalbutamol acts as a bronchodilator to ease breathing, ambroxol thins and loosens thick mucus, and guaifenesin increases the volume of airway secretions to help clear them from the lungs. As a generic formulation, Vocuff is distributed through Skyways Healthcare's PCD (Propaganda Cum Distribution) franchise network.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Vocuff.